LGND vs. EPD
Compare and contrast key facts about Ligand Pharmaceuticals Incorporated (LGND) and Enterprise Products Partners L.P. (EPD).
Performance
LGND vs. EPD - Performance Comparison
Loading graphics...
LGND vs. EPD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LGND Ligand Pharmaceuticals Incorporated | 5.60% | 76.45% | 50.03% | 6.92% | -56.75% | 55.31% | -4.64% | -23.15% | -0.90% | 34.76% |
EPD Enterprise Products Partners L.P. | 19.96% | 9.45% | 28.00% | 17.71% | 18.32% | 21.40% | -23.61% | 21.88% | -1.32% | 4.24% |
Fundamentals
LGND:
$4.22B
EPD:
$82.68B
LGND:
$6.10
EPD:
$2.65
LGND:
32.74
EPD:
14.27
LGND:
0.28
EPD:
2.29
LGND:
15.20
EPD:
1.57
LGND:
4.15
EPD:
2.75
LGND:
$268.09M
EPD:
$52.60B
LGND:
$175.85M
EPD:
$7.17B
LGND:
$143.43M
EPD:
$9.92B
Returns By Period
In the year-to-date period, LGND achieves a 5.60% return, which is significantly lower than EPD's 19.96% return. Over the past 10 years, LGND has underperformed EPD with an annualized return of 6.06%, while EPD has yielded a comparatively higher 12.26% annualized return.
LGND
- 1D
- 3.64%
- 1M
- 0.68%
- YTD
- 5.60%
- 6M
- 12.71%
- 1Y
- 89.89%
- 3Y*
- 39.49%
- 5Y*
- 5.25%
- 10Y*
- 6.06%
EPD
- 1D
- -3.17%
- 1M
- 4.70%
- YTD
- 19.96%
- 6M
- 25.15%
- 1Y
- 18.72%
- 3Y*
- 21.83%
- 5Y*
- 19.58%
- 10Y*
- 12.26%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LGND vs. EPD — Risk / Return Rank
LGND
EPD
LGND vs. EPD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and Enterprise Products Partners L.P. (EPD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LGND | EPD | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.61 | 1.00 | +1.61 |
Sortino ratioReturn per unit of downside risk | 3.24 | 1.40 | +1.85 |
Omega ratioGain probability vs. loss probability | 1.40 | 1.20 | +0.20 |
Calmar ratioReturn relative to maximum drawdown | 6.48 | 1.23 | +5.25 |
Martin ratioReturn relative to average drawdown | 15.70 | 3.48 | +12.22 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LGND | EPD | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.61 | 1.00 | +1.61 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.12 | 1.15 | -1.03 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.13 | 0.51 | -0.37 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.54 | -0.44 |
Correlation
The correlation between LGND and EPD is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
LGND vs. EPD - Dividend Comparison
LGND has not paid dividends to shareholders, while EPD's dividend yield for the trailing twelve months is around 5.75%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LGND Ligand Pharmaceuticals Incorporated | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPD Enterprise Products Partners L.P. | 5.75% | 6.74% | 6.63% | 7.51% | 7.79% | 8.20% | 9.09% | 6.23% | 6.97% | 6.29% | 5.88% | 5.90% |
Drawdowns
LGND vs. EPD - Drawdown Comparison
The maximum LGND drawdown since its inception was -93.34%, which is greater than EPD's maximum drawdown of -58.78%. Use the drawdown chart below to compare losses from any high point for LGND and EPD.
Loading graphics...
Drawdown Indicators
| LGND | EPD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.34% | -58.78% | -34.56% |
Max Drawdown (1Y)Largest decline over 1 year | -13.21% | -15.40% | +2.19% |
Max Drawdown (5Y)Largest decline over 5 years | -70.11% | -18.06% | -52.05% |
Max Drawdown (10Y)Largest decline over 10 years | -81.94% | -58.04% | -23.90% |
Current DrawdownCurrent decline from peak | -27.27% | -3.67% | -23.60% |
Average DrawdownAverage peak-to-trough decline | -44.71% | -10.17% | -34.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.45% | 5.44% | +0.01% |
Volatility
LGND vs. EPD - Volatility Comparison
Ligand Pharmaceuticals Incorporated (LGND) has a higher volatility of 11.92% compared to Enterprise Products Partners L.P. (EPD) at 5.70%. This indicates that LGND's price experiences larger fluctuations and is considered to be riskier than EPD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LGND | EPD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.92% | 5.70% | +6.22% |
Volatility (6M)Calculated over the trailing 6-month period | 24.57% | 11.89% | +12.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.70% | 18.77% | +15.93% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.98% | 17.08% | +26.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.12% | 24.26% | +20.86% |
Financials
LGND vs. EPD - Financials Comparison
This section allows you to compare key financial metrics between Ligand Pharmaceuticals Incorporated and Enterprise Products Partners L.P.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LGND vs. EPD - Profitability Comparison
LGND - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 59.67M. Therefore, the gross margin over that period was 0.0%.
EPD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Enterprise Products Partners L.P. reported a gross profit of 2.00B and revenue of 13.79B. Therefore, the gross margin over that period was 14.5%.
LGND - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 13.84M and revenue of 59.67M, resulting in an operating margin of 23.2%.
EPD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Enterprise Products Partners L.P. reported an operating income of 1.94B and revenue of 13.79B, resulting in an operating margin of 14.1%.
LGND - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported a net income of 44.78M and revenue of 59.67M, resulting in a net margin of 75.1%.
EPD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Enterprise Products Partners L.P. reported a net income of 1.64B and revenue of 13.79B, resulting in a net margin of 11.9%.